Angiotensin Receptor

Choose Selective Angiotensin Receptor Inhibitors

Angiotensin Receptor Products

  • All (20)
  • Angiotensin Receptor Inhibitor (1)
  • Angiotensin Receptor Antagonists (18)
  • New Angiotensin Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7678 Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Arch Toxicol, 2022, 96(4):1065-1074
Cardiovasc Res, 2021, 117(5):1391-1401
Neurotox Res, 2021, 10.1007/s12640-021-00414-1
E0039New A-779

A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.

Elife, 2022, 11e72266
S0326 Olodanrigan (EMA401) Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
S1359 Losartan Potassium (DuP 753) Losartan Potassium (DuP 753, MK 954) is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
Front Cardiovasc Med, 2021, 8:692856
Biochem Biophys Res Commun, 2021, 544:1-7
Adv Healthc Mater, 2021, e2001856
S1507 Irbesartan Irbesartan (BMS-186295, SR-47436) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
Front Physiol, 2019, 10:681
Antiviral Res, 2015, 120:140-6
S1578 Candesartan (CV-11974) Candesartan (CV-11974) is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Front Pharmacol, 2022, 13:828643
Hypertension, 2021, 77(5):1723-1736
Sci Rep, 2020, 8;10(1):6046
S1604 Olmesartan Medoxomil Olmesartan Medoxomil (CS-866) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.
Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505
Sci Rep, 2015, 5:8116
S1738 Telmisartan Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Exp Ther Med, 2022, 23(3):216
Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00196-X
Eur J Pharmacol, 2021, S0014-2999(21)00845-1
S1894 Valsartan (CGP-48933) Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
Arch Toxicol, 2022, 96(4):1065-1074
Int J Mol Sci, 2021, 22(16)8598
Sci Rep, 2015, 5:8116
S2037 Candesartan Cilexetil Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.
Exp Biol Med, 2015, 10.1177/1535370215576312
J Cardiovasc Pharmacol, 2015, 66(3):285-93
Sci Rep, 2015, 5:8116
S3046 Azilsartan Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.
Front Pharmacol, 2021, 12:774709
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2015, 5:8116
S3057 Azilsartan Medoxomil Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.
Sci Rep, 2015, 5:8116
S4102 Eprosartan Mesylate Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2016, 10.1038/srep25694
Sci Rep, 2015, 5:8116
S4975 Fimasartan Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Drug Metab Dispos, 2020, 48(12):1264-1270
S5067 Losartan Losartan is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.
Cell Death Discov, 2022, 8(1):134
Front Pharmacol, 2021, 12:765951
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
S5581 Olmesartan Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.
bioRxiv, 2020, 10.1101/2020.10.13.337774
S5980 Losartan Carboxylic Acid (EXP-3174) Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. Losartan Carboxylic Acid inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Biomedicines, 2021, 10(1)86
S7098 PD123319 PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Cell Res, 2021, 10.1038/s41422-020-00464-8
Int J Biochem Cell Biol, 2020, 121:105703
Neurosci Lett, 2020, 716:134684
P1085 Angiotensin II human Acetate Angiotensin II (angII) is an octapeptide hormone which affects the activities of heart, kidney, vasculature and brain. It works via binding to specific receptors present on cell membranes.
S7678 Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Arch Toxicol, 2022, 96(4):1065-1074
Cardiovasc Res, 2021, 117(5):1391-1401
Neurotox Res, 2021, 10.1007/s12640-021-00414-1
E0039New A-779

A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.

Elife, 2022, 11e72266
S0326 Olodanrigan (EMA401) Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
S1359 Losartan Potassium (DuP 753) Losartan Potassium (DuP 753, MK 954) is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
Front Cardiovasc Med, 2021, 8:692856
Biochem Biophys Res Commun, 2021, 544:1-7
Adv Healthc Mater, 2021, e2001856
S1507 Irbesartan Irbesartan (BMS-186295, SR-47436) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
Front Physiol, 2019, 10:681
Antiviral Res, 2015, 120:140-6
S1578 Candesartan (CV-11974) Candesartan (CV-11974) is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Front Pharmacol, 2022, 13:828643
Hypertension, 2021, 77(5):1723-1736
Sci Rep, 2020, 8;10(1):6046
S1604 Olmesartan Medoxomil Olmesartan Medoxomil (CS-866) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.
Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505
Sci Rep, 2015, 5:8116
S1738 Telmisartan Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Exp Ther Med, 2022, 23(3):216
Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00196-X
Eur J Pharmacol, 2021, S0014-2999(21)00845-1
S1894 Valsartan (CGP-48933) Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
Arch Toxicol, 2022, 96(4):1065-1074
Int J Mol Sci, 2021, 22(16)8598
Sci Rep, 2015, 5:8116
S2037 Candesartan Cilexetil Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.
Exp Biol Med, 2015, 10.1177/1535370215576312
J Cardiovasc Pharmacol, 2015, 66(3):285-93
Sci Rep, 2015, 5:8116
S3046 Azilsartan Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.
Front Pharmacol, 2021, 12:774709
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2015, 5:8116
S3057 Azilsartan Medoxomil Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.
Sci Rep, 2015, 5:8116
S4102 Eprosartan Mesylate Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2016, 10.1038/srep25694
Sci Rep, 2015, 5:8116
S4975 Fimasartan Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Drug Metab Dispos, 2020, 48(12):1264-1270
S5067 Losartan Losartan is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.
Cell Death Discov, 2022, 8(1):134
Front Pharmacol, 2021, 12:765951
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
S5581 Olmesartan Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.
bioRxiv, 2020, 10.1101/2020.10.13.337774
S5980 Losartan Carboxylic Acid (EXP-3174) Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. Losartan Carboxylic Acid inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Biomedicines, 2021, 10(1)86
S7098 PD123319 PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Cell Res, 2021, 10.1038/s41422-020-00464-8
Int J Biochem Cell Biol, 2020, 121:105703
Neurosci Lett, 2020, 716:134684
E0039New A-779

A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.

Elife, 2022, 11e72266
Tags: Angiotensin Receptor inhibitor|Angiotensin Receptor agonist|Angiotensin Receptor activator|Angiotensin Receptor inducer|Angiotensin Receptor antagonist|Angiotensin Receptor signaling pathway|Angiotensin Receptor assay kit